钙拮抗剂是近年来治疗心血管病药物的一项重要进展。除临床常用的维拉帕米、硝苯吡啶和硫氮(艹卓)酮外,新近又研制了许多双氢吡啶类钙拮抗剂,它们在临床和药理作用方面有其共同处,但也各有其特点.有些已应用于临床。本文对4种新型钙拮抗剂的药理作用和临床应用作简要介绍。一、尼群地平本品是双氢吡啶衍生物,化学结构与硝苯吡啶相类似。135例轻、中度高血压病患者口服尼群地平5～20mg,每日二次,可显著降低卧位和立位血压,并轻度增加脉率。另有报道给予本品后,血压降低伴心排出量显著增加,但继续治疗一周,血压仍维持在较低水平,而心排血量恢复接近正常水平.该药对血管平滑肌钙通道有较强的选择性抑制作用,对血管的亲和力比心肌大10倍,故有较强的 Calcium antagonists in recent years is an important progress in the treatment of cardiovascular disease drugs. In addition to the clinically used verapamil, nifedipine, and thiadiazole ketones, a number of dihydropyridine calcium antagonists have recently been developed that have their clinical and pharmacological effects in common, but also Has its own characteristics. Some have been used in clinical. This article describes the pharmacological effects and clinical applications of four new types of calcium antagonists. First, nitrendipine This product is a dihydropyridine derivative, chemical structure and nifedipine similar. 135 cases of mild to moderate hypertensive patients oral nitrendipine 5 ~ 20mg, twice daily, can significantly reduce supine and orthostatic blood pressure, and mild increase in pulse rate. Another report given this product, the blood pressure decreased with cardiac output increased significantly, but continued treatment for one week, blood pressure remained at a low level, and cardiac output recovered to near normal levels of the drug on vascular smooth muscle calcium channel is stronger Selective inhibition, the affinity of the blood vessels 10 times larger than the myocardium, it is stronger